论文部分内容阅读
慢性丙型肝炎(慢丙肝)的治疗常不满意。作者给30例慢丙肝病人重组α或γ干扰素,以评估大剂量长时间rIFN-α的疗效,并确定rIFN-γ的效果。病人和方法:慢丙肝患者30例,SGPT持续增高1年以上,经肝穿活检确诊。患者随机分3组;组I,10例,其中慢性活肝7例;肝硬化3例,以rIFN-α皮下注射,每周3次,每次7.5MU/M~2,1～3月;以后每次5 MU/M~2,4～6月;再以每次2.5 MU/M~2,6～12月。组Ⅱ,10例,慢迁肝、慢活肝、肝硬化各为2、6、2例,给以皮注rIFN-γ,每次2 MU/M~2,共6个月。组Ⅲ,对照组,慢迁肝、慢活肝、肝硬化各为2、5、3例,未经IFN治疗。治疗期间及随访(18个月)中,按月作临床、生化、血液学检查。19例患者(组Ⅰ,6例;组Ⅱ,6例;组Ⅲ,7例)第13个月再次活检,按组织学活动指数(HAI)、病理诊断及临床表现作比较。
Chronic hepatitis C (chronic hepatitis C) treatment is often not satisfied. The authors gave 30 patients with chronic hepatitis C patients recombinant α or γ interferon to evaluate the efficacy of high-dose long-term rIFN-α, and to determine the effect of rIFN-γ. Patients and Methods: 30 patients with chronic hepatitis C, SGPT continued to increase for more than 1 year, diagnosed by liver biopsy. Patients were randomly divided into three groups; group I, 10 cases, of which 7 cases of chronic live liver; liver cirrhosis in 3 cases, rIFN-α subcutaneous injection three times a week, each 7.5MU / M ~ 2,1 to 3 months; After each 5 MU / M ~ 2,4 ~ June; then each 2.5 MU / M ~ 2,6 ~ December. Group Ⅱ, 10 cases, slow-moving liver, slow-living liver, cirrhosis of the liver were 2, 6, 2 cases, respectively, to skin rIFN-γ, 2 MU / M ~ 2 each for 6 months. Group Ⅲ, control group, slow moving liver, slow living liver, liver cirrhosis were 2,5,3 cases, without IFN treatment. During the treatment and follow-up (18 months), monthly, clinical, biochemical, hematological examination. Thirteen patients (group I, 6; group II, 6; group III, 7) were biopsied again on the thirteenth month and compared by histological activity index (HAI), pathological diagnosis and clinical manifestations.